Efficacy and Safety of Tofacitinib in Pediatric Alopecia Areata: A Prospective Observational Study
May 2025
in “
Journal of Pharmacy And Bioallied Sciences
”
Studysummary In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study evaluated the efficacy and safety of tofacitinib in treating moderate-to-severe pediatric alopecia areata over a 24-week period. Conducted with children aged 6-16 years who had not responded to conventional therapies, the study found that tofacitinib led to significant hair regrowth, with most participants achieving complete or near-complete regrowth. The treatment was well-tolerated, with mostly mild to moderate side effects. Despite the positive outcomes, the study's observational nature and short follow-up period limit the ability to draw definitive conclusions about long-term safety and relapse rates. Further research with randomized controlled trials and longer follow-up is recommended to better understand the long-term implications of tofacitinib use in this population.
